Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate adipocyte differentiation and gene expression. We tested the hypothesis that the Pro12Ala variant of PPAR-g g2 is associated with obesity and type 2 diabetes-related traits in 921 subjects from the San Antonio Family Heart Study. Subjects with at least one Ala allele (n 210) had signi®cantly higher body mass index (P 0.015) and waist circumference (P 0.028) and signi®cantly higher levels of serum leptin (P 0.022) than those without the allele. Further studies will determine whether the Pro12Ala variant itself, or other genetic variation at PPAR-g g, is responsible for this association with measures of obesity in Mexican Americans.
Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors that act as transcription factors and regulate adipocyte differentiation and gene expression. A number of endogenous (fatty acids and prostaglandins) and synthetic (thiazolidinediones) ligands for PPAR-g stimulate adipocyte differentiation and improve insulin sensitivity. 1 Therefore, PPAR-g has become a candidate gene in studies of obesity and type 2 diabetes.
The human PPAR-g gene encodes several alternatively-spliced transcripts, giving rise to a PPAR-g2 isoform having an additional 30 amino acids in its amino-terminus than PPAR-gl. 2 A Pro12Ala variant of PPAR-g2 has been identi®ed, 3 and in vitro, the Ala allele has decreased binding af®nity for its promoter element, and reduced ability to transactivate promoters. 4 Association studies using this polymorphism have met with equivocal results: in a study of two American Caucasian cohorts the Ala variant was associated with increased body mass index (BMI), 5 while in Finns, this variant was associated with decreased BMI and improved insulin sensitivity. 4 In a Danish study, the Ala allele was associated with higher BMI and a higher weight gain over time in obese men, but a lower BMI and a slower weight gain in controls. 6 The Pro allele has been associated with increased risk for type 2 diabetes in Japanese Americans, 4 while other studies have failed to detect any signi®cant associations in either Caucasians 7 or Japanese. 8 A Pro115Gln variant identi®ed in obese German Caucasian subjects was associated with obesity, and was shown to accelerate differentiation of cells into adipocytes and increase accumulation of triglycerides in adipose tissue. 9 Another PPAR-g DNA polymorphism, that does not alter the protein, has recently been characterized 3, 10 and was reported to be associated with serum leptin levels in obese, but not lean, individuals. 10 We tested the hypothesis that the Pro12Ala variant is associated with measures of obesity and type 2 diabetes in Mexican Americans. Subjects for this study, 921 individuals from 24 multigenerational families, were participants of the San Antonio Family Heart Study, a population-based family study of atherosclerosis and its risk factors carried out among low-income Mexican Americans from San Antonio, Texas. 11 BMI, waist circumference, and waist to hip ratio (WHR) were measured by trained nurses, and total fat mass was obtained by bioimpedance. 11 Leptin and insulin concentrations were measured from fasting serum samples. 11, 12 All procedures were approved by the Institutional Review Board, and all subjects gave informed consent.
The Pro12Ala variant of PPAR-g2 was typed using a polymerase chain reaction (PCR)-based strategy according to Yen et al. 3 The allele frequency of the Ala variant estimated by maximum likelihood methods was 11.1%, similar to that which has been reported in Caucasian populations, 4, 5 and consistent with Hardy-Weinberg expectations.
We estimated mean trait levels for each genotype using the measured genotype approach, which uses maximum likelihood methods to obtain parameter estimates conditioned on the pedigree structures. 13 All analyses were adjusted for the effects of age, age, 2 and sex. Serum insulin and leptin concentrations were transformed by their natural logarithms prior to analyses. Statistical testing was performed by comparing the likelihoods of nested models using the likelihood ratio test. Initial analyses revealed no signi®cant differences in trait means between individuals with the AlaaAla and AlaaPro genotypes (P b 0.20 for all traits). We therefore compared the mean trait levels between subjects with and without the Ala allele. In the full model, we allowed a separate effect of the Pro allele, while in the nested model, we did not. Twice the difference between likelihoods of the two models is distributed asymptotically as a chisquare statistic with degrees of freedom equal to the difference in the number of parameters in the models being compared (in this case, 1). All analyses were performed using the SOLAR software program. 14 Mean levels of each trait adjusted for age and sex are shown in Table 1 according to genotype. Heritability ranged from 39 to 45% for all traits, except for WHR, where heritability was 19%. Subjects with at least one PPAR-g2 Ala allele had signi®cantly higher BMI (P 0.011), waist circumference (P 0.028), and leptin levels (P 0.021) than subjects without this allele. Following strati®cation by sex, there was no evidence for a stronger effect of the Ala allele in women than in men as has been previously reported (data not shown). 5 The PPAR-g2 polymorphism explained approximately 1% of the variation in these traits. There was no difference in the proportion of subjects with type 2 diabetes, nor in WHR, total fat mass, or mean insulin levels between genotype groups.
Our result, taken together with results from other studies, suggests that variation in PPAR-g may contribute to obesity in some populations. Our data shows that while there is signi®cant association with obesityrelated traits, its contribution to the observed variation is small. This would explain why in our genome scan in a subset of this population (n 476) we were unable to obtain unequivocal evidence for linkage with these traits in the region of PPARg on chromosome 3 (i.e. LOD score for leptin 1.32, P 0.007). Still, the pharmacologic importance of PPAR-g as the target of the thiazolidinedione class of diabetes drugs that may act through affecting adipocyte metabolism cannot be ignored. 1 And the association of obesity with PPARg genetic variation demonstrates that the metabolic pathways of PPARg could have pharmacologic importance in its treatment, as well.
Whether the Pro12Ala variant of PPAR-g2 itself is responsible for these effects on obesity related traits requires further studies such as those by Deeb et al 4 to con®rm the functional role of the mutation. Given that in some populations, the association with obesity measures is with the Ala allele, and in others with the Pro allele, additional factors would have to be present in these populations to modify the effect of this variant, if it is indeed responsible for the associations. Since thePPAR-g locus encodes at least two protein isoforms (PPAR-g1 and PPAR-g2), additional variation in the PPAR-g gene, in linkage disequilibrium with the PPAR-g2 Pro12Ala variant, could also contribute to some of these associations. Further genetic studies will help determine the role PPAR-g plays in obesity and type 2 diabetes. Association of PPAR-g2 Pro12Ala with BMI and leptin SA Cole et al
